NCI-2019-04523

A Phase 1/2 study of IDE196 in patients with solid tumors harboring GNAQ/11 mutations or PRKC fusions

It's a Phase 1/2 study looking at a drug called IDE196 in patients with certain types of solid tumors. These tumors have mutations in GNAQ/11 or PRKC genes.

Phase 1/2 study: A study that assesses the safety, effectiveness, and how well the treatment works

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT03947385

Clinical Trial Site: Columbia

To see all available clinical trials click here.